Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-015
jRCT2051200127Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of lenvatinib, pembrolizumab, oxaliplatin, capecitabine, folinic acid and 1 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with adverse events and 5 more. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2051200127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200127.